Jones Day is representing STERIS Corporation on its recommended offer to acquire Synergy Health plc in a cash and stock transaction valued at approximately $1.9 billion. STERIS is a major provider of infection prevention and other procedural products and services, focused primarily on healthcare, medical devices, pharmaceutical, and research.

STERIS has established New STERIS, which is incorporated in England and Wales, to undertake the transaction. Following completion of the combination, New STERIS will become the holding company of Synergy (by way of a court approved scheme of arrangement) and STERIS (by way of a merger governed by Ohio law).

Synergy shareholders are expected to hold approximately 30 percent of New STERIS and STERIS stockholders approximately 70 percent at closing.

It is intended that the New STERIS Shares will be listed on the New York Stock Exchange.

New STERIS is expected to have a combined revenue of approximately $2.6 billion and employ approximately 14,000 people throughout its operations in over 60 countries around the world.

The closing, which is subject to conditions, including shareholder, antitrust approval, and the approval of the High Court, is expected to take place by March 31, 2015.

In addition to M&A representation, Jones Day is providing U.K. banking, antitrust, and employee benefits advice regarding this transaction.